These are rare tumors that start in the early nervous system. They can occur in babies and young children. They are called 'neuroectodermal' because they originate from a specific part of the early embryo's nervous system. These tumors can be benign (not cancerous) or malignant (cancerous).
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for Neuroectodermal Tumors?
Neuroectodermal tumors are cancers that start in cells descended from the neuroectoderm, a layer of tissue in the early embryo that goes on to form the brain, spinal cord and nerves. The name describes where a tumor's cells come from rather than one disease. It is an umbrella term covering a family of quite different cancers, and the specific type determines how the tumor behaves, how it is treated and what the outlook is. Most people meet the phrase through primitive neuroectodermal tumor, or PNET, an older label for fast-growing tumors made of very immature cells, seen mostly in children, teenagers and young adults. Doctors have since replaced that label with more precise names. A PNET in the brain is now classified as a central nervous system (CNS) embryonal tumor, the most common of which is medulloblastoma, a tumor of the cerebellum at the back of the brain. A PNET outside the brain, in bone or soft tissue, is now called Ewing sarcoma. Neuroblastoma, a childhood cancer of immature nerve cells that usually begins in the adrenal glands above the kidneys, belongs to the same broad family. Symptoms depend on where the tumor grows. Brain tumors can cause morning headaches, vomiting, clumsiness and vision changes. Ewing sarcoma usually causes pain and swelling around a bone. Neuroblastoma often shows up as a lump in the belly, neck or chest.
These tumors arise when genetic changes cause immature cells to keep growing and dividing instead of maturing normally. In most cases the reason those changes happen is unknown. A minority of cases are linked to inherited conditions. Li-Fraumeni syndrome, Gorlin syndrome (nevoid basal cell carcinoma syndrome), Turcot syndrome, Rubinstein-Taybi syndrome and Fanconi anemia raise the risk of medulloblastoma, and Fanconi anemia also raises the risk of Ewing sarcoma. Some neuroblastomas involve a gene change passed down from a parent. Because a family history does not always reveal an inherited condition, doctors may recommend genetic counseling after diagnosis, which can matter for brothers, sisters and future children.
Diagnosis starts with imaging to find the tumor and see whether it has spread. For a suspected brain tumor that usually means MRI of the brain and spine, and a lumbar puncture (spinal tap) may check the spinal fluid for tumor cells. For bone or soft tissue tumors it can include X-rays, MRI, CT and bone scans. Neuroblastoma workups often add urine tests and an MIBG scan, in which a small amount of a radioactive tracer is injected and collects in neuroblastoma cells so a scanner can find them. The diagnosis itself is made from a tissue sample, either removed during surgery or taken by biopsy, and examined by a pathologist. Molecular tests on that sample look for specific gene and chromosome changes. These tests are now central, because tumors that look alike under the microscope can be very different diseases. In one study, a large share of brain tumors originally labeled PNET turned out on expert review to be other tumors, including high-grade gliomas (fast-growing tumors of the brain's supporting cells), which have a much poorer outlook. Molecular results also help predict how a tumor will behave and guide how intensive treatment needs to be. Because the details are so specialized, a second review of the pathology at an experienced center is common and reasonable.
Treatment is planned by a team experienced in these cancers, usually led by a pediatric oncologist for children and young adults, and depends on the specific tumor type, its location, whether it has spread, the person's age and the tumor's molecular features. Most plans combine several approaches. Surgery aims to remove as much of the tumor as can be taken out safely, since the amount left behind affects outlook. Radiation therapy treats remaining tumor cells. For brain embryonal tumors in older children, radiation often covers the whole brain and spinal cord because these tumors can spread within the brain and spinal cord. In very young children, doctors often rely on surgery and intensive chemotherapy first and delay or limit radiation, because radiation can affect a developing brain. For brain embryonal tumors and Ewing sarcoma, chemotherapy is part of nearly every plan. In some cases very high doses are used, followed by a stem cell transplant using the person's own previously collected blood-forming cells to restore the bone marrow. Ewing sarcoma is treated with chemotherapy combined with surgery, radiation or both to the main tumor, sometimes adding high-dose chemotherapy with a stem cell transplant. Neuroblastoma treatment ranges widely: some low-risk tumors are watched closely without treatment, while high-risk disease may need surgery, chemotherapy, radiation, high-dose therapy with stem cell rescue, radioactive MIBG therapy, immunotherapy or targeted drugs. Clinical trials are a standard part of care for many of these rare cancers.
Treatment is usually intensive and can last many months, with hospital stays, frequent clinic visits and blood counts that drop between chemotherapy cycles. Outlook varies enormously across this family of tumors. It depends on the exact type, where it started, whether it has spread, how much could be removed and the tumor's molecular profile, so survival figures for one type do not apply to another. The care team is the best source for an individual estimate. After surgery for a tumor in the back of the brain, such as medulloblastoma, some children develop cerebellar mutism syndrome, with delayed speech, trouble swallowing, poor balance and mood changes. Some of these problems can be treated or managed, and the care team can arrange therapy and support. Because treatment is given while the body is still growing, survivors can develop late effects that appear months or years afterward. These can include slowed growth, hormone and thyroid problems, hearing loss, heart effects, difficulties with learning, memory and attention, and a higher risk of a second cancer. Follow-up therefore continues long after treatment ends, with scans to watch for recurrence and survivorship care to catch and manage late effects, including school support when needed.
See a doctor about symptoms that persist or worsen, especially headaches that are worse in the morning or ease after vomiting, new clumsiness or trouble walking, double vision, or in a baby a head that is growing quickly or missed developmental milestones. A lump in a limb, the chest or the belly, bone pain or swelling that does not settle, a bone that breaks without a clear reason, or an unexplained fever also deserve evaluation. These signs usually have other causes, but they are worth checking. A brain tumor can block the flow of fluid around the brain and raise pressure inside the skull, and this can worsen quickly. Unusual sleepiness, or headaches and vomiting that are getting worse, need same-day contact with a doctor or the care team. A person who is hard to wake or newly confused, has a severe headache with repeated vomiting, or has a seizure needs emergency care right away. During treatment, call the care team right away for a fever of 100.5 F (38 C) or higher, chills, or redness and swelling where a catheter enters the body. Chemotherapy lowers the white blood cells that fight infection, and an infection at that point can become life threatening quickly. Ask your team before giving fever-reducing medicine, which can hide a fever. Between visits, report new or returning symptoms after treatment, since these can be the first sign of recurrence.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Neuroectodermal Tumors is like, what's helped you, or ask the community a question.